| Drug ID: | Drug196 |
|---|---|
| Drug Name: | Desonide |
| CID: | 5311066 |
| DrugBank ID: | DB01260 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03437005, , NCT02624544, , NCT03386032, , NCT03758365, , NCT00828412, , NCT02732314, , NCT02286700, , NCT01467362, , NCT01542138 |
| Molecular Formula: | C24H32O6 |
| Molecular Weight: | 416.5 g/mol |
| Isomeric SMILES: | C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O |
| Synonyms: | DESONIDE; 638-94-8; Prednacinolone; Desonate; Desonida; Topifug; Desilux; Desonidum; Verdeso; Apolar |
| Phase 0: | 0 |
| Phase 1: | 2 |
| Phase 2: | 0 |
| Phase 3: | 3 |
| Phase 4: | 5 |
| Description: | A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1375 | 5311066 | Desonide | 301 | ANXA1 | Homo sapiens (human) | None | |
| dt1376 | 5311066 | Desonide | 2908 | NR3C1 | Homo sapiens (human) | Glucocorticoid receptor agonist | |
| dt1377 | 5311066 | Desonide | 367 | AR | Homo sapiens (human) | None | |
| dt1378 | 5311066 | Desonide | 2101 | ESRRA | Homo sapiens (human) | Modulator | |
| dt1379 | 5311066 | Desonide | 2103 | ESRRB | Homo sapiens (human) | Modulator | |
| dt1380 | 5311066 | Desonide | 2104 | ESRRG | Homo sapiens (human) | Modulator | |
| dt1381 | 5311066 | Desonide | 2908 | NR3C1 | Homo sapiens (human) | None | |
| dt1382 | 5311066 | Desonide | 2101 | ESRRA | Homo sapiens (human) | 37713619 | Modulator |
| dt1383 | 5311066 | Desonide | 2103 | ESRRB | Homo sapiens (human) | 37713619 | Modulator |
| dt1384 | 5311066 | Desonide | 2104 | ESRRG | Homo sapiens (human) | 37713619 | Modulator |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT01100112 | (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Colitis, Ulcerative | DRUG: Budesonide | Details |
| NCT01532648 | Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Budesonide MMX|DRUG: Placebo|DRUG: 5-ASA | Details |
| NCT02586259 | Effectiveness of Cortiment in Patients With Ulcerative Colitis | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | DRUG: budesonide MMX | Details |
| NCT00747110 | Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) | PHASE3 | COMPLETED | Dr. Falk Pharma GmbH | Colitis, Ulcerative | DRUG: budesonide|DRUG: mesalazine | Details |
| NCT05976802 | Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis | PHASE4 | NOT_YET_RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: High dose budesonide rectal foam|DRUG: Low … | Details |
| NCT04314375 | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis | PHASE4 | RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Low Dose Budesonide|DRUG: High Dose Budeson… | Details |
| NCT00801723 | (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Budesonide MMX 6 mg Tablet|DRUG: Placebo Ta… | Details |
| NCT02550418 | Budesonide 9 mg Capsules in Active UC | PHASE2 | COMPLETED | Dr. Falk Pharma GmbH | Colitis, Ulcerative | DRUG: Budesonide | Details |
| NCT01349673 | The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | TERMINATED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide Foam | Details |
| NCT01008423 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide|DRUG: Placebo | Details |
| NCT01008410 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide|DRUG: Placebo | Details |
| NL-OMON25521 | Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDED) | Not Available | No | Nestlé 23/08/2021 | None | The results of this prospective study may result … | Details |
| NL-OMON49003 | A randomised controlled trial comparing FMT (fecal microbiota transplantation) after budesonide or placebo in patients with active ulcerative colitis: ;Acronym: the FECBUD trial __ - FMT for ulcerative colitis after initiation of budesonide | Not Available | Not Recruiting | Leids Universitair Medisch Centrum | inflammatory bowel disease ulcerative colitis;10… | Intervention Patients with active ulcerative coli… | Details |
| JPRN-UMIN000031016 | Efficacy and safety of local budesonide for pouchitis - Efficacy of budesonide for pouchitis | PHASE1 | Not Recruiting | Hyogo College of Medicine Department of Inflammatory Bowel Disease | ulcerative colitis pouchitis | None | Details |
| NL-OMON44482 | A randomised controlled trial comparing FECal Microbiota Transplantation after BUDesonide or placebo induction in patients with ulcerative colitis; the FECBUD trial__ - FMT for ulcerative colitis after initiation of budesonide | Not Available | None | Haaglanden Medisch Centrum | inflammatory bowel disease ulcerative colitis;10… | Intervention Patients with active ulcerative coli… | Details |
| NCT05791487 | Combination of Diet and Oral Budesonide for Ulcerative Colitis | None | RECRUITING | Wolfson Medical Center | Ulcerative Colitis|Ulcerative Colitis Chronic Mil… | OTHER: Ulcerative colitis Exclusion Diet|OTHER: P… | Details |
| NCT05341401 | Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis | PHASE2|PHASE3 | UNKNOWN | Assiut University | Ulcerative Colitis Chronic | DRUG: Budesonide MMX|DRUG: Prednisolone | Details |
| NCT00805285 | The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis | PHASE2 | TERMINATED | University of Maryland, Baltimore | Inflammatory Bowel Disease|Ulcerative Colitis | DRUG: Combination Oral Budesonide and Rectal Hydr… | Details |
| NCT03412682 | To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis | PHASE3 | COMPLETED | Ferring Pharmaceuticals | Colitis, Ulcerative | DRUG: Budesonide (6 mg)|DRUG: Budesonide (9 mg)|D… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Colonic budesonide delivery by multistimuli alginate/Eudragit® FS 30D/inulin-ba…
PMID: 36604084
Year: 2023
Relationship Type:
Treatment
Score: 6.5
The purpose of this study was to develop an oral paediatric formulation of budesonide (BUD) for the treatment of inflammatory bowel disease. A formul…
Mucosa associated invariant T and natural killer cells in active and budesonide…
PMID: 36591297
Year: 2022
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Collagenous colitis (CC) is an inflammatory bowel disease, which usually responds to budesonide treatment. Our aim was to study the imm…
Caffeic Acid-Conjugated Budesonide-Loaded Nanomicelle Attenuates Inflammation i…
PMID: 36472567
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis is a multifactorial disease of the gastrointestinal tract which is caused due to chronic inflammation in the colon; it usually sta…
Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the In…
PMID: 36203483
Year: 2022
Relationship Type:
Treatment
Score: 6.5
The aim of the present study was to investigate the therapeutic potential of budesonide- (BDS-) loaded hyaluronic acid nanoparticles (HANPs) for trea…
Bowel frequency (night) and urgent defecation are improved by budesonide foam i…
PMID: 35751039
Year: 2022
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent …
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Ra…
PMID: 35709376
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Proctitis is the least extensive type of ulcerative colitis, for which rectal therapy is rarely studied and is underused. This s…
Reactive oxygen species-scavenging hollow MnO(2) nanozymes as carriers to deliv…
PMID: 34882157
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is related to excessive reactive oxygen species (ROS) and high expression of proinflammatory cytokines. An enzymatic…
Predicting budesonide performance in healthy subjects and patients with Crohn's…
PMID: 33164838
Year: 2021
Relationship Type:
Association
Score: 6.5
Drug product performance might be affected in Crohn's disease (CD) patients compared to healthy subjects due to pathophysiological changes. Since a l…
Efficacy and safety of prolonged release budesonide granules in mesalazine-refr…
PMID: 33028169
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: In patients with mesalazine-refractory ulcerative colitis, systemic corticosteroids are the treatment of choice. OBJECTIVE: To evaluate t…
Nintedanib-Induced Colitis Treated Effectively With Budesonide
PMID: 32766018
Year: 2020
Relationship Type:
Treatment
Score: 6.5
A 68-year-old male with a past medical history of interstitial pulmonary fibrosis (IPF) on nintedanib and chronic nintedanib-induced diarrhea for thr…
Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Bud…
PMID: 32681228
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. AIMS: To assess efficacy…
Evaluation of Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Ther…
PMID: 31974913
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: New formulations for topical treatment of ulcerative colitis with budesonide inclusion complex (BUD(HP-beta-CD)) and poloxamers (PL) were…
Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Respons…
PMID: 31865359
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND In recent years, a plethora of therapeutic agents for ulcerative colitis (UC), especially novel biologics (Bio), have become available. Al…
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A …
PMID: 31700629
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Budesonide-MMX has an established role in the management of relapsing mild-to-moderate ulcerative colitis. Data regarding effectiveness a…
Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-…
PMID: 31243601
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Nanoparticles for colon-drug delivery were designed and evaluated to solve many discrepancy issues as insufficient drug amount at diseased regions, h…
Disseminated Strongyloides stercoralis infection in a dog following long-term t…
PMID: 30938621
Year: 2019
Relationship Type:
Treatment
Score: 6.5
CASE DESCRIPTION: A 1.5-year-old 1.5-kg (3.3-lb) castrated male Pomeranian was examined because of a 10-month history of diarrhea characterized by he…
Prognostic factors of budesonide therapy for the management of Crohn's disease:…
PMID: 30556310
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: This study aimed to identify factors that affect the prognosis of budesonide therapy for Crohn's disease patients. METHOD: Change in Croh…
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative P…
PMID: 29702300
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND & AIMS: Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard…
Pregnancy outcome in four women with inflammatory bowel disease treated with bu…
PMID: 30612500
Year: 2018
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Maintaining disease remission throughout pregnancy in women with inflammatory bowel disease is of the utmost importance to decrease the r…
[Recalcitrant pouchitis treated by budesonide foam:a case report]
PMID: 30416152
Year: 2018
Relationship Type:
Treatment
Score: 6.3
This report presents the case of a 54-year-old man who had undergone restorative proctocolectomy with ileal pouch-anal anastomosis 15 years previousl…